Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Barbie

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
Cancer Discovery|March 5, 2020
TBK1 Activation by VHL Loss in Renal Cell Carcinoma: A Novel HIF-Independent VulnerabilityZiad Bakouny, David A Barbie
The Journal of Clinical Investigation|January 4, 2021
Targeting the mutant p53 secretomeKartik Sehgal, David A Barbie
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2018
<i>RASA1</i>/<i>NF1</i>-Mutant Lung Cancer: Racing to the Clinic?Shunsuke Kitajima, David A Barbie
Cancer Research|December 4, 2019
Clonal Selection Drives NF-κB Activation in Recurrent Nasopharyngeal CarcinomaKartik Sehgal, David A Barbie
Expert Review of Anticancer Therapy|June 15, 2014
Targeting cytokine networks in KRAS-driven tumorigenesisHadrien G Golay, David A Barbie
Cancer Discovery|August 3, 2017
Refining Targeted Therapy Opportunities for <i>BRAF</i>-Mutant MelanomaRussell W Jenkins, David A Barbie
Immunity|October 18, 2018
Tumor cGAMP Awakens the Natural KillersShriram K Sundararaman, David A Barbie
Clinical Advances in Hematology & Oncology : H&O|November 14, 2006
Systemic mastocytosis: current classification and novel therapeutic optionsDavid A Barbie, Daniel J Deangelo
Seminars in Cell & Developmental Biology|June 15, 2016
Inflammation as a driver and vulnerability of KRAS mediated oncogenesisShunsuke Kitajima, Rohit Thummalapalli, David A Barbie
Cell Chemical Biology|April 17, 2026
Degrading TBK1 to disarm VHL-deficient renal cancerHyunwoo Kwon, Alan E Bers, David A Barbie
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Cancer Discovery|March 5, 2020
TBK1 Activation by VHL Loss in Renal Cell Carcinoma: A Novel HIF-Independent VulnerabilityZiad Bakouny, David A Barbie
The Journal of Clinical Investigation|January 4, 2021
Targeting the mutant p53 secretomeKartik Sehgal, David A Barbie
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2018
<i>RASA1</i>/<i>NF1</i>-Mutant Lung Cancer: Racing to the Clinic?Shunsuke Kitajima, David A Barbie
Cancer Research|December 4, 2019
Clonal Selection Drives NF-κB Activation in Recurrent Nasopharyngeal CarcinomaKartik Sehgal, David A Barbie
Expert Review of Anticancer Therapy|June 15, 2014
Targeting cytokine networks in KRAS-driven tumorigenesisHadrien G Golay, David A Barbie
Cancer Discovery|August 3, 2017
Refining Targeted Therapy Opportunities for <i>BRAF</i>-Mutant MelanomaRussell W Jenkins, David A Barbie
Immunity|October 18, 2018
Tumor cGAMP Awakens the Natural KillersShriram K Sundararaman, David A Barbie
Clinical Advances in Hematology & Oncology : H&O|November 14, 2006
Systemic mastocytosis: current classification and novel therapeutic optionsDavid A Barbie, Daniel J Deangelo
Seminars in Cell & Developmental Biology|June 15, 2016
Inflammation as a driver and vulnerability of KRAS mediated oncogenesisShunsuke Kitajima, Rohit Thummalapalli, David A Barbie
Cell Chemical Biology|April 17, 2026
Degrading TBK1 to disarm VHL-deficient renal cancerHyunwoo Kwon, Alan E Bers, David A Barbie
Pageof 12